The $1000 per day price tag of Gilead's new Hepatitis C therapy SOVALDI has triggered the latest round of chatter about high drug prices in the US market. A round-up of reaction and some related articles are below.
Breaking The Bank: Sovaldi And The Cost-Innovation Paradox In The US Healthcare System
Nathan Sadeghi-Nejad (Forbes)
One Of Pharma's Biggest Enemies Goes After The Future's Best-Selling Drug
Matthew Herper (Forbes)
Three Misplaced Assumptions That Could End The Biotech Boom
Matthew Herper (Forbes)
ASCO plans cost-benefit scorecard for cancer meds as prices grow 'unsustainable'
Tracy Staton (FiercePharmaMarketing)
Breaking The Bank: Sovaldi And The Cost-Innovation Paradox In The US Healthcare System
Nathan Sadeghi-Nejad (Forbes)
One Of Pharma's Biggest Enemies Goes After The Future's Best-Selling Drug
Matthew Herper (Forbes)
Three Misplaced Assumptions That Could End The Biotech Boom
Matthew Herper (Forbes)
ASCO plans cost-benefit scorecard for cancer meds as prices grow 'unsustainable'
Tracy Staton (FiercePharmaMarketing)
RSS Feed
